In 2012, Congress created the breakthrough-therapy designation to expedite the testing and approval by the FDA of medications with potential to provide substantial improvement over existing treatments. The authors review the first 4 years of experience with this program.
No takes yet. Share an insight, caveat, or question.
Darrow et al. (2018) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: